Inspire Medical Systems, Inc.
In the published model solve dated 2026-Q2, anchored at $51.82, Inspire Medical Systems, Inc. (INSP) is priced for today's economics sustained for ~30.2 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed June 27, 2026 from SEC EDGAR filings.
• Inspire Medical sells an implanted nerve-stimulation device for obstructive sleep apnea, an alternative to the CPAP mask, and has now treated more than 125,000 patients with the therapy [Source: Inspire FY2025 results, 8-K]. • Growth is decelerating and the price reflects it: 2025 revenue grew 14% to $912 million, but 2026 guidance of $950 million to $1 billion implies only 4% to 10% growth [Source: Inspire 2026 guidance]. • Watch reimbursement and weight-loss drugs; a Medicare prior-authoriza
Is INSP overvalued? See what's priced in →
291 institutional managers reported holding INSP in 13F filings for the quarter ended 2026-03-31. 49 opened new positions that quarter. Held by BlackRock, Vanguard Group, Wellington Management, among others. On the short side, 3.6M shares were sold short as of the 2026-06-15 count, about 13% of shares outstanding (3.8 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
INSP's share count grew 5.4% over the past five years even with $250.02M spent on repurchases. It pays no dividend. Cash returned over the past three years: $250.02M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at INSP over the trailing three years: 2023: 1 buy totaling $15k; 2025: 2 buys totaling $1k. 17 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
INSP's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-02 | -3.5% | -33.3% |
| 2023-11-08 | -20.9% | +47.0% |
| 2024-02-10 | -6.5% | +18.9% |
| 2024-05-08 | -34.9% | -19.6% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
INSP's latest 8-K filings: 2026-07-24 (items 5.02); 2026-07-22 (items 5.02, 9.01); 2026-06-26 (items 7.01, 9.01); 2026-05-05 (items 5.02, 5.03, 5.07, 9.01); 2026-05-04 (items 2.02, 7.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.